INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
MWN-AI** Summary
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company headquartered in Boca Raton, Florida, is scheduled to report its financial results for the fourth quarter ended December 31, 2024, during a conference call on March 27, 2025, at 4:30 PM EDT. Participants are encouraged to join the call by dialing 1-800-225-9448 or 1-203-518-9708 and using the conference ID "INMUNE." A live audio webcast will also be available online, with a transcript and replay provided shortly after.
Focused on harnessing the innate immune system to combat diseases, INmune Bio has developed three innovative product platforms. The first is the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which seeks to selectively neutralize soluble TNF, a significant factor in immune dysfunction. Clinical trials are investiging its efficacy in treating Mild Alzheimer’s disease, Mild Cognitive Impairment, and treatment-resistant depression through its lead candidate, XPro™.
The second platform, Natural Killer Cell Priming, is exemplified by INKmune®, designed to enhance the body's NK cells to fight residual cancer cells. Ongoing trials are assessing its potential in metastatic castration-resistant prostate cancer. Finally, the CORDStrom program utilizes allogeneic human umbilical cord-derived mesenchymal stem cells and recently concluded a randomized trial for recessive dystrophic epidermolysis bullosa.
Despite the promise of its therapies, INmune Bio acknowledges that its products have yet to receive FDA approval and details potential risks associated with clinical development and market conditions. Stakeholders are encouraged to stay informed through the company’s filings with the SEC. For inquiries, CFO David Moss and Investor Relations Head Daniel Carlson can be reached via the provided contact details.
MWN-AI** Analysis
As INmune Bio Inc. (NASDAQ: INMB) prepares to report its fourth-quarter financial results for 2024 on March 27, 2025, investors should closely watch the upcoming conference call for insights into the company’s progress in the clinical-stage biotechnology sector. INmune Bio specializes in innovative therapies targeting the innate immune system, which positions it well amidst growing interest in immune-based treatment modalities.
The key drivers for market interest will be updates on clinical trial outcomes for INmune's lead programs, including the DN-TNF platform aimed at treating neurological disorders such as Alzheimer’s and treatment-resistant depression. Positive preliminary results could bolster investor confidence and attract new capital, while disappointing outcomes may lead to volatility in the stock price.
Additionally, the Natural Killer Cell Priming Platform's ongoing trials in metastatic castration-resistant prostate cancer will also be scrutinized. Progress or setbacks here could significantly impact the narrative surrounding INmune Bio's efficacy and potential market share in oncology.
With funding being a critical aspect of INmune's future, investors should be attentive to any indications of financial stability or partnerships that could facilitate the continuation of their research and development initiatives. Given that many of INmune’s products are still in clinical stages and not yet approved by regulatory agencies, the degree of risk remains elevated.
Furthermore, the company's ability to articulate a clear path forward regarding its CORDStrom platform, which recently completed trials for recessive dystrophic epidermolysis bullosa, will be crucial. A strong corporate update can signal to investors that INmune is navigating its operational challenges effectively and could establish a promising foothold in the biotechnology landscape.
In summary, while INmune Bio poses potential growth opportunities, inherent risks are tied to clinical outcomes and funding. Investors should adopt a balanced approach, staying informed about quarterly results and broader market trends while adhering to prudent risk management practices.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator.
Date: March 27, 2025
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-225-9448 or 1-203-518-9708
Conference ID: INMUNE
A live audio webcast of the call can be accessed by clicking here or using this link:
https://viavid.webcasts.com/starthere.jsp?ei=1704589&tp_key=4727e947f4
A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available by calling 1-844-512-2921 or 1-412-317-6671
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. To learn more, please visit www.inmunebio.com .
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
info@inmunebio.com
Investor Contact:
Daniel Carlson, Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ**
What recent clinical results will INmune Bio Inc. (NASDAQ: INMB) share during their conference call on March 27, 2025, concerning treatments for Mild Alzheimer’s disease and treatment-resistant depression?
How does INmune Bio Inc. (NASDAQ: INMB) plan to address the funding required for ongoing research and development of its various product platforms during the upcoming conference call?
What challenges have been identified by INmune Bio Inc. (NASDAQ: INMB) in the clinical trials for their DN-TNF and NK cell priming platforms, and how do they intend to mitigate these risks moving forward?
Can INmune Bio Inc. (NASDAQ: INMB) provide insights on the regulatory progress of their product candidates and what milestones they aim to achieve in the coming quarters?
**MWN-AI FAQ is based on asking OpenAI questions about INmune Bio Inc. (NASDAQ: INMB).
NASDAQ: INMB
INMB Trading
-5.44% G/L:
$1.565 Last:
646,918 Volume:
$1.66 Open:
